Tsuchikawa Takahiro, Hirano Satoshi, Tanaka Eiichi, Kato Kentaro, Matsumoto Joe, Sichinohe Toshiaki
Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hepatogastroenterology. 2012 Nov-Dec;59(120):2623-6. doi: 10.5754/hge12116.
BACKGROUND/AIMS: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms. Little is known about the mode of recurrence and long term prognosis after resection. We aimed to evaluate the surgical indication, especially for the patients with concomitant multiple liver metastases or extreme local invasions.
The overall survival (OS) and the disease free survival (DFS) were statistically analyzed for twenty one patients with PNETs who underwent surgical intervention in our institute. The patients were divided into 2 groups, G1 NET (grade 1 neuroendocrine tumor: n=11) and G2 NET (grade 2 neuroendocrine tumor: n=10), according to WHO 2010 classification. The radical operation was indicated if curative resection were expected to be achievable. Otherwise,alternative multi-disciplinary treatments were introduced especially for the hepatic metastasis or repeated recurrences.
Median follow-up period was 37 months (range 7-69). OS was 100% at 3 years and 86% at 5 years. DFS was 62% at 3 years and 39% at 5 years. Disease recurrence developed more frequently in G2 NET, compared to G1 NET. However, there was statistically no difference for the OS between these two groups.
Appropriate radical operation with multi-disciplinary treatments could contribute to the patients' survival in the treatment strategy of PNETs.
背景/目的:胰腺神经内分泌肿瘤(PNETs)是罕见肿瘤。对于其切除术后的复发模式和长期预后了解甚少。我们旨在评估手术指征,尤其是对于伴有多发肝转移或局部侵犯严重的患者。
对在我院接受手术干预的21例PNETs患者的总生存期(OS)和无病生存期(DFS)进行统计学分析。根据世界卫生组织2010年分类,将患者分为2组,G1 NET(1级神经内分泌肿瘤:n = 11)和G2 NET(2级神经内分泌肿瘤:n = 10)。如果预期可实现根治性切除,则进行根治性手术。否则,尤其针对肝转移或反复复发引入多学科替代治疗。
中位随访期为3个月(范围7 - 69个月)。3年总生存率为100%,5年为86%。3年无病生存率为62%,5年为39%。与G1 NET相比,G2 NET疾病复发更频繁。然而,两组之间的总生存期在统计学上无差异。
在PNETs的治疗策略中,适当的根治性手术联合多学科治疗有助于患者生存。